menu
    • menu
    [{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Series B Financing","leadProduct":"Tildacerfont","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Spruce Biosciences \/ Omega Funds","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Omega Funds"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tildacerfont","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Spruce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tildacerfont","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spruce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tildacerfont","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spruce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Tildacerfont","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spruce Biosciences \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"5am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Tildacerfont","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Spruce Biosciences \/ 5am Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ 5am Ventures"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tildacerfont","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spruce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tildacerfont","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spruce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tildacerfont","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spruce Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"HMNC Brain Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Tildacerfont","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spruce Biosciences \/ HMNC Brain Health","highestDevelopmentStatusID":"6","companyTruncated":"Spruce Biosciences \/ HMNC Brain Health"}]

    Find Clinical Drug Pipeline Developments & Deals by Spruce Biosciences

    Menu

    Spruce Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Spruce Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Spruce Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : HMNC Brain Health

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Spruce and HMNC Brain Health Announce Collaboration for Major Depressive Disorder

                            Details : The collaboration aims to develop Spruce’s investigational candidate, tildacerfont, a second-generation CRF1 receptor antagonist, with HMNC’s companion diagnostic, for major depressive disorder.

                            Brand Name : SPR001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 04, 2024

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : HMNC Brain Health

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Spruce Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Spruce Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Spruce Biosciences Reports Topline Results from CAH Trials

                            Details : SPR001 (tildacerfont) is a potent and highly selective, non-steroidal, once-daily oral antagonist of the CRF1 receptor, which is being developed for adult classic congenital adrenal hyperplasia (CAH)

                            Brand Name : SPR001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 13, 2024

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Spruce Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Spruce Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Spruce Biosciences Completes Enrollment in CAHmelia-204 for Classic Adrenal Hyperplasia

                            Details : SPR001 (tildacerfont), a selective oral, non-steroidal, CRF1 receptor antagonist, is being tested in phase 2 trials for treating congenital adrenal hyperplasia.

                            Brand Name : SPR001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 22, 2024

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Spruce Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Spruce Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Spruce Biosciences Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal Hyper...

                            Details : SPR001 (tildacerfont) is a potent and highly selective, non-steroidal, oral antagonist of the CRF1 receptor, which is investigated for the treatment of adult Classic Congenital Adrenal Hyperplasia.

                            Brand Name : SPR001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 18, 2023

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Spruce Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Spruce Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : 5am Ventures

                            Deal Size : $53.6 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Spruce Biosciences Announces $53.6 Million Private Placement Financing

                            Details : The Company expects to use the net proceeds from the Offering, for the advancement of the Company’s clinical development programs, including SPR001 (tildacerfont) and for working capital and other general corporate purposes.

                            Brand Name : SPR001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 09, 2023

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : 5am Ventures

                            Deal Size : $53.6 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Spruce Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Spruce Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Kaken Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement t...

                            Details : SPR001 (tildacerfont) is a potent and highly selective, non-steroidal, oral antagonist of the corticotropin-releasing factor (CRF) 1 receptor. The CRF1 receptor is abundantly expressed in the pituitary gland where it is the primary regulator of the HPA a...

                            Brand Name : SPR001

                            Molecule Type : Small molecule

                            Upfront Cash : $15.0 million

                            January 05, 2023

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Kaken Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Spruce Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Spruce Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference

                            Details : Spruce is developing its wholly-owned product candidate, SPR001 (tildacerfont), as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH).

                            Brand Name : SPR001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 31, 2022

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Spruce Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Spruce Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Spruce Bio Presents Phase 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia at European Co...

                            Details : Tildacerfont has been evaluated in 171 patients across seven clinical trials in which it has been generally well tolerated. No drug-related serious adverse events have been reported related to tildacerfont treatment.

                            Brand Name : SPR001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 24, 2021

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Spruce Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Spruce Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Spruce Biosciences Announces Launch of CAHstudy.com to Initiate Screening of Patients for CAH Clinical Program

                            Details : The CAHmelia clinical program is designed to evaluate the efficacy of tildacerfont, an investigational, oral, once-a-day corticotropin-releasing factor type-1 receptor antagonist, in two placebo-controlled, late stage clinical studies in adults with Clas...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 12, 2020

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Spruce Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Spruce Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Omega Funds

                            Deal Size : $88.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Spruce Biosciences Raises $88 Million in Series B Financing

                            Details : The proceeds will be used to further fund the clinical development of the company’s lead product, tildacerfont, in classic congenital adrenal hyperplasia (CAH) and other conditions.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 19, 2020

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Omega Funds

                            Deal Size : $88.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth